These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system. Danese S; Papa A Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):826-8. PubMed ID: 18794594 [TBL] [Abstract][Full Text] [Related]
9. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Saibeni S; Bottasso B; Spina L; Bajetta M; Danese S; Gasbarrini A; de Franchis R; Vecchi M Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757 [TBL] [Abstract][Full Text] [Related]
10. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism. Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920 [TBL] [Abstract][Full Text] [Related]
11. Tissue factor pathway inhibitor and thrombin-activatable carboxypeptidase B for prediction of early atherosclerosis in gouty arthritis. Uyanik MS; Pamuk GE; Pamuk ON; Tuncel SA Thromb Res; 2014 Aug; 134(2):526-30. PubMed ID: 24974054 [TBL] [Abstract][Full Text] [Related]
12. Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer. Koldas M; Gummus M; Seker M; Seval H; Hulya K; Dane F; Kural A; Gumus A; Salepci T; Turhal NS Clin Lung Cancer; 2008 Mar; 9(2):112-5. PubMed ID: 18501098 [TBL] [Abstract][Full Text] [Related]
13. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation. Antovic JP; Blombäck M Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290 [TBL] [Abstract][Full Text] [Related]
14. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission. Erdoğan M; Özbek M; Akbal E; Üreten K Turk J Med Sci; 2019 Oct; 49(5):1381-1385. PubMed ID: 31549496 [TBL] [Abstract][Full Text] [Related]
15. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin. Malyszko J; Suchowierska E; Malyszko JS; Mysliwiec M Perit Dial Int; 2002; 22(5):582-92. PubMed ID: 12455569 [TBL] [Abstract][Full Text] [Related]
16. Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis. Beyazit Y; Sayilir A; Tanoglu A; Kekilli M; Kocak E; Ekiz F; Tas A Intern Med; 2016; 55(14):1831-6. PubMed ID: 27432089 [TBL] [Abstract][Full Text] [Related]
17. Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in rats. Ravindranath TM; Goto M; Demir M; Tobu M; Kujawski MF; Hoppensteadt D; Samonte V; Iqbal O; Sayeed MM; Fareed J Clin Appl Thromb Hemost; 2004 Oct; 10(4):379-85. PubMed ID: 15497025 [TBL] [Abstract][Full Text] [Related]
18. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis. Miljić P; Heylen E; Willemse J; Djordjević V; Radojković D; Colović M; Elezović I; Hendriks D Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688 [TBL] [Abstract][Full Text] [Related]
19. The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis. Cetinkalp S; Tobu M; Karadeniz M; Buyukkeçeci F; Yilmaz C Intern Med; 2009; 48(5):281-5. PubMed ID: 19252348 [TBL] [Abstract][Full Text] [Related]
20. Levels of tissue factor pathway inhibitor in patients with inflammatory bowel disease. Cibor D; Szczeklik K; Mach T; Owczarek D Pol Arch Intern Med; 2019 Apr; 129(4):253-258. PubMed ID: 31038478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]